Since PI3K is involved in T-cell activation as well, the optimization of the schedule regimens may be considered; otherwise employing specific PI3K isoform inhibitors (not relevant for T-cell activity, i.e., PI3K-β) without anti-tumor activity and sparing of T-cell function could be taken into consideration. This evidence concerns the gene PPIB and neoplasm.